title: Induction of p34cdc2 in mouse parotid glands upon activation of beta1-adrenergic receptors.
abstract: Dramatic morphological, biochemical and cytological changes occur in parotid glands of rats and mice which have been treated with the beta-adrenergic receptor agonist isoproterenol (Ipr). Changes include glandular hypertrophy, induction of tissue-specific proline-rich proteins (PRPs), increases in cAMP, and occurrence of polyploidy. Similar changes also occur after feeding mice polyphenolic compounds commonly referred to as tannins. Data are presented which show that changes in cell cycle proteins are due to stimulation of the beta-adrenergic receptor by either isoproterenol or tannin treatment of mice. Both p34cdc2 mRNA and protein levels were elevated dramatically after mice were treated. Induction of p34cdc2 occurred within 24 hrs. and was transient during treatment. The beta1-adrenergic receptor antagonist atenolol blocked both tissue-specific expression of proline-rich proteins and induction of p34cdc2. Coincident with the increase in p34cdc2, cyclin-dependent kinase complexes containing cyclins A and B increased forty- and ten-fold, respectively. These results show that in mouse parotid glands activation of the beta1-adrenergic receptor by either the administration of isoproterenol or ingestion of dietary tannins induces synthesis of p34cdc2 and most likely contributes to the occurrence of polyploidy.
authors.affiliation: Division of Biology, Howard Hughes Medical Institute, California Institute of Technology, Pasedena 91125, USA.
authors.forename: C A
authors.initials: CA
authors.lastname: Waters
authors.forename: J N
authors.initials: JN
authors.lastname: Morand
authors.forename: R C
authors.initials: RC
authors.lastname: Schatzman
authors.forename: D M
authors.initials: DM
authors.lastname: Carlson
mesh_terms: D000318:Adrenergic beta-Agonists / Q000494:pharmacology*; D000319:Adrenergic beta-Antagonists / Q000494:pharmacology; D000818:Animals; D001114:Areca / Q000009:adverse effects; D001262:Atenolol / Q000494:pharmacology; D016203:CDC2 Protein Kinase / Q000096:biosynthesis* / Q000235:genetics; D002453:Cell Cycle / Q000187:drug effects; D002846:Chromatography, Affinity; D019925:Cyclin A / Q000378:metabolism; D019927:Cyclin E / Q000378:metabolism; D004790:Enzyme Induction / Q000187:drug effects; D047348:Hydrolyzable Tannins / Q000494:pharmacology; D007545:Isoproterenol / Q000494:pharmacology*; D051379:Mice; D008805:Mice, Inbred A; D010306:Parotid Gland / Q000187:drug effects* / Q000201:enzymology; D010946:Plants, Medicinal; D018342:Receptors, Adrenergic, beta-1 / Q000187:drug effects* / Q000502:physiology; D012471:Salivary Proteins and Peptides / Q000096:biosynthesis*; D015398:Signal Transduction / Q000187:drug effects*
chemical_list: D000318:Adrenergic beta-Agonists; D000319:Adrenergic beta-Antagonists; D019925:Cyclin A; D019927:Cyclin E; D047348:Hydrolyzable Tannins; D018342:Receptors, Adrenergic, beta-1; D012471:Salivary Proteins and Peptides; D001262:Atenolol; D016203:CDC2 Protein Kinase; D007545:Isoproterenol